A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine
- PMID: 39706287
- DOI: 10.1016/j.joca.2024.12.002
A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine
Abstract
Objective: Investigational cell therapies have been developed as disease-modifying agents for the treatment of osteoarthritis (OA), including those that inducibly respond to inflammatory factors driving OA progression. However, dysregulated inflammatory cascades do not specifically signify the presence of OA. Here, we deploy a synthetic receptor platform that regulates cell behaviors in an arthritis-specific fashion to confine transgene expression to sites of cartilage degeneration.
Design: A single-chain variable fragment specific for type II collagen (CII) that is exposed in damaged cartilage was used to produce a synthetic Notch (synNotch) receptor that enables "CII-synNotch" mesenchymal stromal cells (MSCs) to recognize degraded cartilage. Artificial signaling induced by both CII-treated culture surfaces and primary tissues was measured via fluorescence and luminescence assays. Separate studies measured the ability of CII-synNotch to govern cartilage anabolic activity of MSCs. Finally, a co-culture with ATDC5 chondrocytes was used to determine whether CII-synNotch MSCs can protect chondrocytes against deleterious effects of pro-inflammatory interleukin-1 in a CII-dependent manner.
Results: CII-synNotch MSCs are highly and selectively responsive to CII, but not type I collagen, as measured by luminescence assays, fluorescence microscopy, and concentrations of secreted transgene products in culture media. CII-synNotch cells exhibit the capacity to distinguish between healthy and damaged cartilage tissue and constrain transgene expression to regions of exposed CII fibers. Receptor-regulated production of cartilage anabolic and anti-inflammatory transgenes was effective to mediate cartilage regenerative functions.
Conclusion: This work demonstrates proof-of-concept that the synNotch platform guides MSCs for spatially regulated, disease-dependent delivery of OA-relevant biologic drugs.
Keywords: Cell therapy; Osteoarthritis; SynNotch; Synthetic biology.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Update of
-
A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine.bioRxiv [Preprint]. 2024 Feb 15:2024.01.31.578281. doi: 10.1101/2024.01.31.578281. bioRxiv. 2024. Update in: Osteoarthritis Cartilage. 2024 Dec 18:S1063-4584(24)01501-2. doi: 10.1016/j.joca.2024.12.002 PMID: 38352576 Free PMC article. Updated. Preprint.
Similar articles
-
A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine.bioRxiv [Preprint]. 2024 Feb 15:2024.01.31.578281. doi: 10.1101/2024.01.31.578281. bioRxiv. 2024. Update in: Osteoarthritis Cartilage. 2024 Dec 18:S1063-4584(24)01501-2. doi: 10.1016/j.joca.2024.12.002 PMID: 38352576 Free PMC article. Updated. Preprint.
-
Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. PMID: 36137063 Free Books & Documents. Review.
-
Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.Health Technol Assess. 2022 Oct;26(44):1-310. doi: 10.3310/ZUCE8371. Health Technol Assess. 2022. PMID: 36321689 Free PMC article.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article. Review.
LinkOut - more resources
Full Text Sources